A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
You may also be interested in...
COVID Vaccine ‘Miracle’ May Set Unrealistic Expectations For US Supply Chains
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.
CEOs Tell Trump Tax Cuts Could Bring More Biopharma Plants To US
Lower taxes could entice biopharmaceutical sector to focus more on the US as it seeks to expand biotech manufacturing capacity where it can find highly educated and experienced scientists.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.